Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Barrett, A John  [Clear All Filters]
Journal Article
A Barrett J. Acute myeloid leukaemia and the immune system: implications for immunotherapy. Br J Haematol. 2019.
Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, A Barrett J, Battiwalla M, et al. Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution. Biol Blood Marrow Transplant. 2018.
Bollard CM, A Barrett J. Cytotoxic T lymphocytes for leukemia and lymphoma. Hematology Am Soc Hematol Educ Program. 2014;2014(1):565-569.
Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, et al. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS. Br J Haematol. 2016.
Russell Y Cruz C, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, A Barrett J, Ito S, et al. Infusion of donor-derived CD19-redirected-virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase I study. Blood. 2013.
Ito S, A Barrett J, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, et al. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2014;14(1):95-104.
Jain P, Tian X, Cordes S, Chen J, Cantilena CR, Bradley C, Panjwani R, Chinian F, Keyvanfar K, Battiwalla M, et al. Over-expression of PD-1 does not predict leukemic relapse after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2018.